by TractManager | Jan 31, 2022 | Emerging Technology Report
Blarcamesine (proposed name: Anavex 2-73) is an investigational, orally available small molecule that acts as a muscarinic agonist and an agonist of the intracellular sigma-1 chaperone protein. It is in development for the treatment of early Alzheimer disease. If you...
by TractManager | Jan 31, 2022 | Emerging Technology Report
Donanemab is an investigational, intravenously administered amyloid beta-directed antibody proposed for the treatment of Alzheimer disease.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Jan 27, 2022 | Emerging Technology Report
Etranacogene dezaparvovec (formerly AMT-061) is an investigational recombinant gene transfer therapy product designed to help patients with hemophilia B produce sufficient plasma levels of endogenous coagulation factor IX (FIX). The main therapeutic goal is long-term...
by TractManager | Jan 27, 2022 | Molecular Test Assessment
This report evaluates the analytical validity, clinical validity, and clinical utility of the TruGraf test for kidney transplant rejection.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Jan 27, 2022 | Emerging Technology Report
SER-109 is an investigational microbiota-based product for fecal microbiota transplantation (FMT). It is proposed to prevent recurrent Clostridioides (formerly Clostridium) difficile infection (CDI) in adults with a history of 3 or more CDI episodes within a 12-month...
Recent Comments